Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.55 |
| ▸ | ITGAV | P06756 | 7/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 9/20 | 0.54 |
| ▸ | MC5R | P33032 | 9/20 | 0.54 |
| ▸ | MC3R | P41968 | 9/20 | 0.54 |
| ▸ | MC1R | Q01726 | 9/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22970320 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21766911 | 0.94 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL19605458 | 0.94 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL20888358 | 0.94 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21257776 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL19412647 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL15160074 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24253221 | 0.92 | ITGB3 (0.49) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL19605457 | 0.92 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL24253307 | 0.92 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066665-B2 | Antitumor drug delivery formulation | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210187005-A1 | PHARMACEUTICAL COMPOSITION | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-11020418-B2 | Unit structure-type pharmaceutical composition for nucleic acid delivery | NANOCARRIER CO., LTD. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-10993960-B1 | Pharmaceutical composition | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2021-05-04 | — | — | US | disclosed |
| US-20180153920-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | NANOCARRIER CO., LTD. (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180042955-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | NANO MRNA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9808480-B2 | Unit structure-type pharmaceutical composition for nucleic acid delivery | NANOCARRIER CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3141243-A1 | PHARMACEUTICAL COMPOSITION | The University of Tokyo (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-2781536-B1 | BLOCK COPOLYMER HAVING PHENYLBORONIC ACID GROUP INTRODUCED THEREIN, AND USE THEREOF | UNIV TOKYO (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9278075-B2 | Particle composition and pharmaceutical composition using particle composition | NANOCARRIER CO., LTD. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150080454-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | NANOCARRIER CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20140017328-A1 | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION USING PARTICLE COMPOSITION | NANOCARRIER CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | Fundacion de la Communidad Valenciana Centro de Investigacion principe felipe (ES) | 2011-11-24 | — | — | US | disclosed |
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-11-29 | — | — | US | disclosed |
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153920-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | POLRMT, SSU72, PARG | ITGB3 3989/4885ITGAV 1728/4885ITGB1 3175/4885 |
| US-11020418-B2 | Unit structure-type pharmaceutical composition for nucleic acid delivery | POLRMT, SSU72, CTDSP1 | ITGB3 3881/4885ITGAV 1943/4885ITGB1 3109/4885 |
| US-20140017328-A1 | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION USING PARTICLE COMPOSITION | H1-0, H1-10, H1-2 | ITGB3 1926/4885ITGAV 2025/4885ITGB1 1192/4885 |
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | VEGFA, FLT4, FLT1 | ITGB3 105/4885ITGAV 68/4885ITGB1 171/4885 |
| US-20210187005-A1 | PHARMACEUTICAL COMPOSITION | ABCB11, ABCB1, ABCG2 | ITGB3 711/4885ITGAV 869/4885ITGB1 206/4885 |
| US-10993960-B1 | Pharmaceutical composition | ABCB11, ABCB1, ABCG2 | ITGB3 711/4885ITGAV 869/4885ITGB1 206/4885 |
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | HCAR1, DHFR, FOLR1 | ITGB3 1861/4885ITGAV 1395/4885ITGB1 1793/4885 |
| US-11066665-B2 | Antitumor drug delivery formulation | SLC67A1, MCTS1, SLC47A1 | ITGB3 3721/4885ITGAV 3110/4885ITGB1 2345/4885 |
| US-20150080454-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | CTDSP1, SMC1A, SSU72 | ITGB3 3321/4885ITGAV 1331/4885ITGB1 2440/4885 |
| US-20180042955-A1 | UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY | POLRMT, SSU72, CTDSP1 | ITGB3 3881/4885ITGAV 1943/4885ITGB1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.